Figure 3A-D. New frontiers for drug development.

(A) Isoform-selective inhibitors bind to an individual protein isoform within the cell. (B) Antibody drug conjugates bind to cell surface antigens and are internalized into the cell where they release a cytotoxic payload to induce cell death. (C) Proteolysis Targeting Chimeras (PROTACs) bind both mutant proteins and E3 ubiquitin ligase, facilitating proteasomal degradation of the target. (D) Protein refolders enable mutant proteins to regain wildtype conformation and activity.